PED MED: WADING THROUGH ADHD DRUG OPTIONS

Parents, patients and physicians who decide to launch a pharmaceutical course of treatment for attention-deficit/hyperactivity disorder must wade through a large pool of offerings -- twice as many as available in Europe -- with little scientific data to guide them, market analysts say.

Monsters and Critics (http://news.monstersandcritics.com/lifestyle/consumerhealth/article_1155001.php/Ped_Med_Wading_through_ADHD_drug_options)